Dr. Pooja Ghatalia presents findings from RETAIN-2, a single-arm phase 2 non-randomized trial evaluating a ...

In this opening segment, Dr. Marwan Fakih and Dr. Richard Kim outline the current epidemiology, biology, and therapeutic ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the best small-cap stocks with huge growth potential. Nuvation Bio Inc.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

cDivision of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA dDivision of Hematology Oncology, Department of Medicine, Moffitt Cancer Center, Tampa, FL, ...

In this analysis, researchers aimed to determine whether intermediate dose escalation is beneficial in resectable, stage III NSCLC patients who receive definitive concurrent chemoradiation followed by ...

At a median follow-up of 145.1 months, the 10-year overall survival rate was 28.3% with chemoradiotherapy boost and 29.9% with surgery. Long-term survival following chemoradiation is comparable to ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to the ongoing ...

A new study published in the Journal of American Medical Association showed that active surveillance may be appropriate for carefully chosen patients, particularly those with high surgical risk or low ...